Transfusion · 2026
Comparative platelet activation profile between pooled granulocyte concentrates (PGC) versus apheresis (APC) and buffy coat (BC-PC) method.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cognasse Fabrice, Desseux Karine, Artero Véronique, Duraffourg Veronique, Crespe Damien, Eyraud Marie-Ange, Arthaud Charles-Antoine, Prier Amélie, Maillot Victorine, Duchez Anne-Claire, Chavarin Patricia, Hamzeh-Cognasse Hind
Аннотация
BACKGROUND: Granulocyte transfusion remains a therapeutic option for patients with severe neutropenia or granulocyte dysfunction, though its clinical benefit is still debated. Traditional pooled granulocyte concentrates (PGC) are produced by donor stimulation and apheresis, procedures that are costly and ethically restrictive. To overcome these limitations, PGC derived from buffy coat layers (BC) have emerged as a simpler and safer alternative, yet little is known about their platelet composition and activation profile.
STUDY DESIGN /METHODS: Whole blood donations (n = 256) were processed into BC, pooled (20 BC per batch), and reconstituted to form PGC20 units. Hematologic parameters and platelet activation markers (CD41, CD62P, CD63) were analyzed by automated counting and flow cytometry and compared with standard apheresis (APC) and buffy coat-derived platelet concentrates (BC-PC).
RESULTS: PGC show a high platelet concentration comparable to BC-PC, with an increased mean platelet volume. The elevated expression of CD62P and CD63 confirms marked platelet activation, while the slight decrease in CD41 suggests membrane alteration during processing, indicating a mixed platelet-granulocyte product with immunomodulatory potential that requires optimization for safe transfusional use.
CONCLUSIONS: PGC derived from buffy coat pools combines high granulocyte yield with an activated platelet population. This bioactive platelet component may enhance immune interactions but warrants further optimization to ensure transfusion safety and product standardization.
STUDY DESIGN /METHODS: Whole blood donations (n = 256) were processed into BC, pooled (20 BC per batch), and reconstituted to form PGC20 units. Hematologic parameters and platelet activation markers (CD41, CD62P, CD63) were analyzed by automated counting and flow cytometry and compared with standard apheresis (APC) and buffy coat-derived platelet concentrates (BC-PC).
RESULTS: PGC show a high platelet concentration comparable to BC-PC, with an increased mean platelet volume. The elevated expression of CD62P and CD63 confirms marked platelet activation, while the slight decrease in CD41 suggests membrane alteration during processing, indicating a mixed platelet-granulocyte product with immunomodulatory potential that requires optimization for safe transfusional use.
CONCLUSIONS: PGC derived from buffy coat pools combines high granulocyte yield with an activated platelet population. This bioactive platelet component may enhance immune interactions but warrants further optimization to ensure transfusion safety and product standardization.